3Schneck DW, Knopp RH, Ballantyne CM, et al. Compara- tive effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without ac- tive arterial disease[ J ]. Am J Cardiol, 2003 ; 91 : 33-41.
二级参考文献8
1Martin PD,Dane AL,Schneck DW,et al.An open-label,randomized,three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinefic properties of rosuvastatin and fenofibric acid in healthy male volunteers[J].Clin Ther,2003;2:459-471.
2Martin PD,Warwick MJ,Dane AL,et al.A double-blind,randomized,incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers[J].Clin Ther,2003;8:2215-2224.
3Martin PD,Warwick MJ,Dane AL,et al.Metabolism,excretion,and pharmacokinefics of rosuvastatin in healthy adult male volunteers[J].Clin Ther,2003;11:2822-2835.
4Stalker TJ,Lefer AM,Scalia R.A new HMG-CoA reductase inhibitor,rosuvastatin,exerts anti-inflammatory effects on the microvascular endothelium:the role of mevalonic acid[J].Br J Pharmacol,2001;133:406-412.
5Hull CK,Martin PD,Warwick MJ,et al.Quantification of the N-desmethyl metabolite of rosuvastatin in human plasma by automated SPE followed by HPLC with tandem MS detection[J].J Pharm Biomed Analy,2004;35:609-614.
6Schneck DW,Knopp RH,Ballantyne CM,et al.Comparative effects of rosuvastatin and atorvastatin across their dose ranges in pafients with hypercholesterolemia and without active arterial disease[J].Am J Cardiol,2003;91:33-41.
7Brewer HB Jr.Benefit-risk assessment of rosuvastatin 10 to 40 milligrams[J].Am J Cardiol,2003;92:23K-29K.
8Martin PD,Warwick MJ,Dane AL,et al.Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteer[J].Clin Ther,2003;25:2553-2563.
1Steven E. Nissen,Stephen J. Nicholls,Ilks Sipahi,Peter Libby,Joel S. Raichlen,Christie M. Ballantyne,Jean Davignon,Raimund Erbel,Jean Charles Fruchart,Jean-Claude Tardif,Paul Schoenhagen,Tim Crowe,Valerie Cain,Kathy Wolski,Marlene Coormastic,E. Murat Tuzcu,仝其广（译）,王淑敏（译）,胡大一（校）.极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验[J].美国医学会杂志（中文版）,2006,25(4):215-223. 被引量：349
6Hanaa A. El Gendy,Noha M. Elsharnouby.Safety and vasopressor effect of rosuvastatin in septic patients[J].Egyptian Journal of Anaesthesia.2014
7Kazuyoshi Kaneko,Hiroki Saito,Tetsuya Takahashi,Nobuyuki Kiribayashi,Koki Ohmi,Toshiki Sasaki,Takeshi Niizeki,Shigeo Sugawara,Masahiro Akasaka,Isao Kubota.Rosuvastatin Improves Plaque Morphology in Cerebral Embolism Patients with Normal Low-Density Lipoprotein and Severe Aortic Arch Plaque[J].Journal of Stroke and Cerebrovascular Diseases.2014
8Rajkiran Mahalwar,Deepa Khanna.Pleiotropic antioxidant potential of rosuvastatin in preventing cardiovascular disorders[J].European Journal of Pharmacology (-).2013(1-3)
9Evan A. Stein,Donald G. Vidt,James Shepherd,Valerie A. Cain,Deborah Anzalone,Michael D. Cressman.Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: A retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program[J].Atherosclerosis.2012(2)
10Judith Hsia,Jean G. MacFadyen,John Monyak,Paul M. Ridker.Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin[J].Journal of the American College of Cardiology.2011(16)
